Qufeng Xuanbi Formula inhibited benzo[a]pyrene-induced aggravated asthma airway mucus secretion by AhR/ROS/ERK pathway

• Published in: Journal of ethnopharmacology Vol. 319; p. 117203
• Main Authors: Wang, Bo-Han, Tang, Ling-Ling, Sun, Xian-Hong, Zhang, Qian, Liu, Chun-Yang, Zhang, Xiao-Na, Yu, Ke-Yao, Yang, Ying, Hu, Jun, Shi, Xiao-Lu, Wang, Yue, Liu, Li
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 30.01.2024
• Subjects: AhR/ROS/ERK pathway; Asthma; benzo[a]pyrene; MUC5AC; Qufeng Xuanbi formula; benzo[a]pyrene; SOD; Qufeng Xuanbi formula; MUC5AC; Asthma; BaP; QFXBF; AhR/ROS/ERK pathway; ERK1/2; p-ERK1/2; SR1; ROS; OVA; ALI; HPLC; TCM
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2023.117203

Excessive secretion of airway mucus may be an important pathological factor of air pollution-induced acute asthma attacks. Treatment of airway mucus hypersecretion improves asthma aggravated by air pollutants. Qufeng Xuanbi Formula (QFXBF) has been used to treat asthma for more than 30 years. However, whether QFXBF inhibits asthmatic mucus secretion exacerbated by air pollutants has not yet been established. This study aimed to evaluate the effect of QFXBF on airway mucus secretion and the mechanism of action in an air pollutant benzo[a]pyrene (BaP)-induced mouse model of aggravated asthma. Ovalbumin (OVA) and BaP co-exposure were used to establish the aggravated asthma model. The average enhanced pause (Penh), serum OVA-specific IgE, and changes in lung histopathology were determined. 16HBE cells exposed to BaP, treatment with QFXBF, arylhydrocarbon receptor (AhR) signal antagonist SR1, reactive oxygen species (ROS) antagonist NAC, or extracellular signal-regulated kinase (ERK1/2) signal antagonist U0126 were established to investigate the effect of QFXBF on BaP-induced mucus secretion and its target. The mRNA and protein expression levels of MUC5AC in the lung tissue and 16HBE cells were examined. We also studied the effect of QFXBF on ROS production. Finally, the protein expression of AhR, phospho-extracellular signal-regulated kinases (p-ERK1/2), and ERK1/2 in 16HBE cells and lung tissues was determined by western blotting. Administration of QFXBF significantly alleviated the pathological symptoms, including Penh, serum OVA-specific IgE, and changes in lung histopathology in a BaP-induced mouse model of aggravated asthma. QFXBF inhibited MUC5AC expression in asthmatic mice and 16HBE cells exposed to BaP. ROS production, AhR expression, and ERK1/2 phosphorylation were significantly increased in BaP-induced asthmatic mice and 16HBE cells. Signaling pathway inhibitors StemRegenin 1 (SR1), NAC, and U0126 significantly inhibitedBaP-induced MUC5AC expression in 16HBE cells. SR1 reversed Bap-induced ROS production and ERK activation, and NAC inhibited Bap-induced ERK activation. In addition, QFXBF regulated AhR signaling, inhibited ROS production, reversed ERK activation, and downregulated mucus secretion to improve asthma aggravated by air pollutant BaP. QFXBF can ameliorate mucus secretion in BaP-induced aggravated asthmatic mice and 16HBE cells, and the specific mechanism may be related to the inhibition of the AhR/ROS/ERK signaling pathway. [Display omitted] •Qufeng Xuanbi formula (QFXBF) inhibited BaP-induced high expression of MUC5AC by inhibiting AhR.•QFXBF blocks the activation of AhR, thus inhibiting AhR-mediated ROS generation.•QFXBF ameliorates airway mucus secretion via the AhR/ROS/ERK pathway.